LIVIMODE
Light-based functional in vivo monitoring of diseases related enzymes
| Coordinatore | INSTITUT JOZEF STEFAN
Organization address
address: Jamova 39 contact info |
| Nazionalità Coordinatore | Slovenia [SI] |
| Totale costo | 6˙867˙435 € |
| EC contributo | 4˙850˙785 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-11-01 - 2013-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT JOZEF STEFAN
Organization address
address: Jamova 39 contact info |
SI (LJUBLJANA) | coordinator | 784˙925.00 |
| 2 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 1˙089˙040.00 |
| 3 |
EUROPEAN MOLECULAR BIOLOGY LABORATORY
Organization address
address: Meyerhofstrasse 1 contact info |
DE (HEIDELBERG) | participant | 844˙222.40 |
| 4 |
FREIE UNIVERSITAET BERLIN
Organization address
address: Kaiserswertherstrasse 16-18 contact info |
DE (BERLIN) | participant | 510˙600.00 |
| 5 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 383˙864.00 |
| 6 |
UNIVERSITAT AUTONOMA DE BARCELONA
Organization address
address: Campus UAB -BELLATERRA- s/n contact info |
ES (CERDANYOLA DEL VALLES) | participant | 319˙899.60 |
| 7 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 307˙474.28 |
| 8 |
FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPE FELIPE
Organization address
address: CALLE EDUARDO PRIMO YUFERA 3 contact info |
ES (VALENCIA) | participant | 302˙850.00 |
| 9 |
SANOFI-AVENTIS DEUTSCHLAND GMBH
Organization address
address: Industriepark Hoechst - Building G879 contact info |
DE (Frankfurt/Main) | participant | 170˙000.00 |
| 10 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 92˙909.71 |
| 11 |
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT
Organization address
address: Pierre Brossolette 1 contact info |
FR (Chilly Mazarin) | participant | 45˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'LIVIMODE aims to develop specific tools for non invasive in vivo imaging of disease related molecular events. Such tools are of high relevance for disease detection, staging, developing animal models of human disease, and evaluating novel therapies. We propose to use optical imaging, which is optimally suited for this task as it provides excellent sensitivity and allows visualizing molecular events via a fluorescent signal. While optical imaging technology has rapidly evolved over the last years, the availability of SMART (activatable) imaging agents that change their fluorescence properties upon disease related events, remains a critical gap. The LIVIMODE project proposes to combine expertises in medicinal chemistry, pharmacology and imaging in a conceptually new approach in designing SMART agents. In particular, we will (i) translate established strategies in medicinal/pharmaceutical chemistry to design highly selective SMART probes and (ii) optimize the cell/tissue specificity of probes integrating concepts from polymer and protein based targeted drug delivery. We will generate a toolset of highly selective targeted SMART probes for at least 10 disease-relevant proteases. The selection of target proteases is based on their relevance in disease processes that cannot yet be monitored with non invasive technology. These include (i) the development of tumor microenvironment as a critical factor in oncogenesis, (ii) tumor hypoxia and angiogenesis, and (iii) inflammatory and degenerative processes in osteoarthritis. LIVIMODE has established animal models for these conditions and will use in vivo optical imaging to evaluate the novel SMART probes as tools for monitoring disease progression and drug efficacy. This will enhance our knowledge of disease mechanisms and our ability to rapidly characterize drug candidates for in vivo efficacy (proof-of-efficacy). Selected SMART probes will be optimized to assess their potential as clinical diagnostics.'
Altri progetti dello stesso programma (FP7-HEALTH)
MICROENVIMET (2008)
Understanding and fighting metastasis by modulating the tumour microenvironment through interference with the protease network
Read MoreNEUROPAIN (2014)
Neuropathic pain: biomarkers and druggable targets within the endogenous analgesia system
Read MoreIMPACT (2012)
Improving the lives of Parkinson’s Disease patients while reducing side-effects through tailored deep brain stimulation
Read More